This developer and seller of microfluidic systems has seen one negative estimate revision in the last 30 days. However, the Zacks Consensus Estimate has remained unchanged over the same period. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Fluidigm currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked Med-Instruments stock is Inogen, Inc. (INGN) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment